Sorafenib microcrystalline preparation and preparation method and application thereof

The invention provides a sorafenib microcrystalline preparation and a preparation method and application thereof. The sorafenib microcrystalline preparation can realize long-acting inhibition of HCC cell proliferation and tumor formation by single injection of sorafenib in tumor tissues. Meanwhile,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: WANG TAO, LIANG ERGUANG, FENG FAN, WANG ZHENGSHUAI
Format: Patent
Sprache:chi ; eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator WANG TAO
LIANG ERGUANG
FENG FAN
WANG ZHENGSHUAI
description The invention provides a sorafenib microcrystalline preparation and a preparation method and application thereof. The sorafenib microcrystalline preparation can realize long-acting inhibition of HCC cell proliferation and tumor formation by single injection of sorafenib in tumor tissues. Meanwhile, the drug release experiment definitely proves that the sorafenib microcrystalline preparation can ensure the long-term retention of the drug in tumor tissues. Although the solubility and bioavailability of sorafenib are limited, the properties of sorafenib can be improved to a certain extent after sorafenib is prepared into a microcrystal preparation, and the release rate of the drug can be adjusted by controlling the particle size of microcrystals. 本发明提供了一种索拉非尼微晶制剂及其制备方法和用途,使索拉非尼在肿瘤组织内的单次注射即能够实现长效抑制HCC细胞增殖与成瘤作用。同时,药物释放实验明确证实,索拉非尼的微晶制剂能够保证药物在肿瘤组织内部的较长期留存。尽管索拉非尼的溶解度与生物利用度有限,但将其制备为微晶制剂后能够对其性质进行一定程度的改善,通过控制微晶的粒径也能够对药物的释放速率进行调整。
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN111840208A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN111840208A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN111840208A3</originalsourceid><addsrcrecordid>eNrjZAgNzi9KTEvNy0xSyM1MLspPLqosLknMycnMS1UoKEotSCxKLMnMz1NIzEtB4eemlmTkp4CFEwsKcjKTIcIlGalFqflpPAysaYk5xam8UJqbQdHNNcTZQze1ID8-tbggMTk1L7Uk3tnP0NDQwsTAyMDC0ZgYNQB2Czo9</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Sorafenib microcrystalline preparation and preparation method and application thereof</title><source>esp@cenet</source><creator>WANG TAO ; LIANG ERGUANG ; FENG FAN ; WANG ZHENGSHUAI</creator><creatorcontrib>WANG TAO ; LIANG ERGUANG ; FENG FAN ; WANG ZHENGSHUAI</creatorcontrib><description>The invention provides a sorafenib microcrystalline preparation and a preparation method and application thereof. The sorafenib microcrystalline preparation can realize long-acting inhibition of HCC cell proliferation and tumor formation by single injection of sorafenib in tumor tissues. Meanwhile, the drug release experiment definitely proves that the sorafenib microcrystalline preparation can ensure the long-term retention of the drug in tumor tissues. Although the solubility and bioavailability of sorafenib are limited, the properties of sorafenib can be improved to a certain extent after sorafenib is prepared into a microcrystal preparation, and the release rate of the drug can be adjusted by controlling the particle size of microcrystals. 本发明提供了一种索拉非尼微晶制剂及其制备方法和用途,使索拉非尼在肿瘤组织内的单次注射即能够实现长效抑制HCC细胞增殖与成瘤作用。同时,药物释放实验明确证实,索拉非尼的微晶制剂能够保证药物在肿瘤组织内部的较长期留存。尽管索拉非尼的溶解度与生物利用度有限,但将其制备为微晶制剂后能够对其性质进行一定程度的改善,通过控制微晶的粒径也能够对药物的释放速率进行调整。</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20201030&amp;DB=EPODOC&amp;CC=CN&amp;NR=111840208A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20201030&amp;DB=EPODOC&amp;CC=CN&amp;NR=111840208A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>WANG TAO</creatorcontrib><creatorcontrib>LIANG ERGUANG</creatorcontrib><creatorcontrib>FENG FAN</creatorcontrib><creatorcontrib>WANG ZHENGSHUAI</creatorcontrib><title>Sorafenib microcrystalline preparation and preparation method and application thereof</title><description>The invention provides a sorafenib microcrystalline preparation and a preparation method and application thereof. The sorafenib microcrystalline preparation can realize long-acting inhibition of HCC cell proliferation and tumor formation by single injection of sorafenib in tumor tissues. Meanwhile, the drug release experiment definitely proves that the sorafenib microcrystalline preparation can ensure the long-term retention of the drug in tumor tissues. Although the solubility and bioavailability of sorafenib are limited, the properties of sorafenib can be improved to a certain extent after sorafenib is prepared into a microcrystal preparation, and the release rate of the drug can be adjusted by controlling the particle size of microcrystals. 本发明提供了一种索拉非尼微晶制剂及其制备方法和用途,使索拉非尼在肿瘤组织内的单次注射即能够实现长效抑制HCC细胞增殖与成瘤作用。同时,药物释放实验明确证实,索拉非尼的微晶制剂能够保证药物在肿瘤组织内部的较长期留存。尽管索拉非尼的溶解度与生物利用度有限,但将其制备为微晶制剂后能够对其性质进行一定程度的改善,通过控制微晶的粒径也能够对药物的释放速率进行调整。</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZAgNzi9KTEvNy0xSyM1MLspPLqosLknMycnMS1UoKEotSCxKLMnMz1NIzEtB4eemlmTkp4CFEwsKcjKTIcIlGalFqflpPAysaYk5xam8UJqbQdHNNcTZQze1ID8-tbggMTk1L7Uk3tnP0NDQwsTAyMDC0ZgYNQB2Czo9</recordid><startdate>20201030</startdate><enddate>20201030</enddate><creator>WANG TAO</creator><creator>LIANG ERGUANG</creator><creator>FENG FAN</creator><creator>WANG ZHENGSHUAI</creator><scope>EVB</scope></search><sort><creationdate>20201030</creationdate><title>Sorafenib microcrystalline preparation and preparation method and application thereof</title><author>WANG TAO ; LIANG ERGUANG ; FENG FAN ; WANG ZHENGSHUAI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN111840208A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2020</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>WANG TAO</creatorcontrib><creatorcontrib>LIANG ERGUANG</creatorcontrib><creatorcontrib>FENG FAN</creatorcontrib><creatorcontrib>WANG ZHENGSHUAI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>WANG TAO</au><au>LIANG ERGUANG</au><au>FENG FAN</au><au>WANG ZHENGSHUAI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Sorafenib microcrystalline preparation and preparation method and application thereof</title><date>2020-10-30</date><risdate>2020</risdate><abstract>The invention provides a sorafenib microcrystalline preparation and a preparation method and application thereof. The sorafenib microcrystalline preparation can realize long-acting inhibition of HCC cell proliferation and tumor formation by single injection of sorafenib in tumor tissues. Meanwhile, the drug release experiment definitely proves that the sorafenib microcrystalline preparation can ensure the long-term retention of the drug in tumor tissues. Although the solubility and bioavailability of sorafenib are limited, the properties of sorafenib can be improved to a certain extent after sorafenib is prepared into a microcrystal preparation, and the release rate of the drug can be adjusted by controlling the particle size of microcrystals. 本发明提供了一种索拉非尼微晶制剂及其制备方法和用途,使索拉非尼在肿瘤组织内的单次注射即能够实现长效抑制HCC细胞增殖与成瘤作用。同时,药物释放实验明确证实,索拉非尼的微晶制剂能够保证药物在肿瘤组织内部的较长期留存。尽管索拉非尼的溶解度与生物利用度有限,但将其制备为微晶制剂后能够对其性质进行一定程度的改善,通过控制微晶的粒径也能够对药物的释放速率进行调整。</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language chi ; eng
recordid cdi_epo_espacenet_CN111840208A
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Sorafenib microcrystalline preparation and preparation method and application thereof
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T15%3A26%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=WANG%20TAO&rft.date=2020-10-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN111840208A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true